卵巢癌患者血清糖链抗原125联合人附睾上皮分泌蛋白4及可溶性间皮素相关肽测定临床价值  

Clinical value of combined detection of serum carbohydrate antigen 125,human epididymis protein and soluble mesothelin related peptide in patients with ovarian cancer

作　　者：邱振华[1] 王茂生[2] 杨长福[2] 魏凯[3] 柯玲[4] 麦大海[5] 

机构地区：[1]高州市人民医院检验科,广东高州525200 [2]高州市人民医院肿瘤科,广东高州525200 [3]茂名市人民医院检验科,广东茂名525000 [4]茂名市人民医院妇科,广东茂名525000 [5]茂名市人民医院肿瘤科,广东茂名525000

出　　处：《中华实用诊断与治疗杂志》2015年第6期583-585,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：广东省科技计划项目(2012B031800344);广东省医学科研基金(A2011671)

摘　　要：目的探讨肿瘤相关糖链抗原125（carbohydrateantigen125，CAl25）联合人附睾上皮分泌蛋白4（humanepididymisprotein4，HE4）和可溶性间皮素相关肽（solublemesothelinrelatedpeptide，sMRP）检测对卵巢癌诊断、预后的临床价值。方法61例卵巢癌患者（卵巢癌组）、42例卵巢良性病变患者（卵巢良性病变组），同期体检健康女性30例为对照组，3组采用化学发光免疫法检测血清CAl25水平，采用ELISA法检测血清HE4和SMRP水平。结果卵巢癌组患者血清CAl25[（272．7±245．6）u／mL]、HE4[（344．5±127．8）pmol／L]、SMRPF（7．20±3．50）nmol／L]水平均高于卵巢良性病变组[CAl25为（24．3±16，7）u／mL，HE4为（37．5±26．2）pmol／L，SMRP为（O．91±0．32）nmol／L]和对照组[CAl25为（17．9±6．5）u／mL，HE4为（31．9±18．1）pmol／L，SMRP为（O．82±0．24）nmol／L]（P〈O．05）；卵巢癌组Ⅲ～Ⅳ期患者血清CAl25E（451．14-301．5）u／mL]、HE4E（294．2±112．3）pmol／L]和SMRPI-（9．28±5．14）nmol／L]水平明显高于I～Ⅱ期[CAl25为（73．5士42．1）u／mL，HE4为（126．6±45．8）pmol／L，SMRP为（4．66±2．75）nmol／L]（P〈0．05）；3项标志物平行联合时诊断卵巢癌的敏感度为93．4％；系列联合时诊断卵巢癌的特异度为100．0％。结论联合检测血清CAt25、HE4和SMRP水平有助于提高卵巢癌的诊断效能，有助于卵巢肿瘤的良恶性鉴别诊断及预后评估。Objective To explore the value of the combined detection of carbohydrate antigen 125（CA125）,human epididymis protein 4（HE4）and soluble mesothelin related peptide（SMRP）to the diagnosis and the prognosis of ovarian cancer.Methods The serum level of CA125 was detected by chemiluminescent immunoassay（CLIA）and the levels of HE4 and SMRP were detected by ELISA respectively in 61 patients with ovarian cancer（cancer group）,42 patients with benign ovarian tumor（benign group）and 30 healthy females（control group）.The detection results combined with the clinical data were statistically analyzed.Results The levels of CA125,HE4 and SMRP were significantly higher in cancer group（（272.7±245.6）u/mL,（344.5±127.8）pmol/L,（7.20±3.50）nmol/L）than those in benign group（（24.3±16.7）u/mL,（37.5±26.2）pmol/L,（0.91±0.32）nmol/L）and control group（（17.9±6.5）u/mL,（31.9±18.1）pmol/L,（0.82±0.24）nmol/L）（p〈0.05）.The levels of CA125,HE4 and SMRP were significantly higher in stageⅢtoⅣ（（451.1±301.5）u/mL,（294.2±112.3）pmol/L,（9.28±5.14）nmol/L）than those in stageⅠtoⅡ（（73.5±42.1）u/mL,（126.6±45.8）pmol/L,（4.66±2.75）nmol/L）in cancer group（p〈0.05）.The sensitivity of parallel combined detection of three indexes was 93.4%,and of serial combined detection was 100.0%.Conclusion The combined detection of serum CA125,HE4 and SMRP contributes to improving the diagnosis efficiency,and has a certain application value to the differential diagnosis of benign and malignant ovarian tumor.

关 键 词：卵巢肿瘤 糖链抗原125 人附睾上皮分泌蛋白4 可溶性间皮素相关肽 

分 类 号：R737.31[医药卫生—肿瘤]